Showing 1 posts of 1 posts found.
BioCryst has scored FDA for its therapy Orladeyo (berotralstat) for reducing or preventing hereditary angioedema (HAE) attacks in patients over …
MHRA awards Innovation Passports to liver cancer and dementia medicines
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
Manchester launches nurse-led clinic to improve kidney transplant outcomes
Androlabs and Majorelle expand testosterone therapy into France
Promatix secures Innovate UK funding to advance bispecific ADC programme